<DOC>
	<DOCNO>NCT00140309</DOCNO>
	<brief_summary>This study placebo-controlled factorial study , randomize study drug ( moxifloxacin vs. ethambutol ) treatment frequency ( daily vs. thrice weekly initial two week daily therapy ) first two month standard treatment ( isoniazid , rifampin , pyrazinamide ) sputum smear-positive pulmonary tuberculosis .</brief_summary>
	<brief_title>TBTC Study 27 : Moxifloxacin v Ethambutol TB Treatment</brief_title>
	<detailed_description>The primary objective Phase II clinical trial compare safety microbiological activity moxifloxacin-containing regimen ( isoniazid , rifampin , pyrazinamide , moxifloxacin [ HRZMoxi ] ) control regimen ( isoniazid , rifampin , pyrazinamide , ethambutol [ HRZE ] ) first two month treatment sputum smear-positive pulmonary tuberculosis . In addition , study evaluate whether intermittent administration ( thrice-weekly first 2 week ) regimens affect tolerability microbiological activity . The assessment microbiological activity sputum culture-conversion . Improved sputum culture conversion 2 month treatment moxifloxacin-containing regimen would support phase 3 clinical trial moxifloxacin treatment regimen less current 6 month standard regimen .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Suspected pulmonary tuberculosis acidfast bacillus stain sputum smear â€“ patient whose sputum culture grow M. tuberculosis M. tuberculosis isolate resistant rifampin discontinue study , follow 14 day detect late toxicity study therapy . Patients extrapulmonary manifestation tuberculosis , addition smearpositive pulmonary disease , eligible enrollment . 2 . Willingness HIV test perform , HIV serostatus know last documented negative HIV test 6 month prior enrollment 3 . 7 few day tuberculosis therapy 6 month precede enrollment 4 . Age &gt; 18 year 5 . Karnofsky score least 60 6 . Signed informed consent 7 . Women childbearing potential must agree practice adequate ( barrier ) method birth control abstain heterosexual sex . 8 . Laboratory parameter within 14 day enrollment : Serum amino aspartate transferase ( AST ) activity le 3 time upper limit normal Serum total bilirubin level le 2.5 time upper limit normal Serum creatinine level le 2 time upper limit normal Hemoglobin level least 7.0 g/dL Platelet count least 50,000/mm3 Serum potassium &gt; 3.0 meq/L Negative pregnancy test ( woman childbearing potential ) 1 . Breastfeeding 2 . Known intolerance study drug 3 . Known allergy fluoroquinolone antibiotic 4 . Current plan therapy first 2 month tuberculosis treatment use drug unacceptable interaction rifampin ( rifabutin substitute rifampin continuation phase therapy ) 5 . Current plan antiretroviral therapy first 2 month tuberculosis treatment 6 . History prolong QT syndrome current plan therapy quinidine , procainamide , amiodarone , sotalol , ziprasidone first 2 month tuberculosis treatment . 7 . Pulmonary silicosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>TB</keyword>
	<keyword>Pulmonary Tuberculosis</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>Pulmonary TB</keyword>
</DOC>